Yes, a testosterone replacement therapy (TRT) prescription typically comes up during full life insurance underwriting, but it does not automatically raise your premium or trigger a decline. Underwriters generally distinguish between documented hypogonadism managed by a physician, which is treated as a controlled medical condition, and unsupervised or off-label testosterone use, which draws more scrutiny. Most men on a well-monitored TRT protocol with normal labs still qualify for standard or better rate classes.
Why Do Life Insurers Ask About Testosterone Therapy?
Life insurance underwriting exists to estimate your mortality risk, and any prescription medication is a data point in that estimate. Full underwriting typically pulls information from three sources beyond your application: a paramedical exam, an Attending Physician Statement (APS) from your doctor, and a Medical Information Bureau (MIB) report that flags prior insurance applications and known risk factors (Ethos, 2026; Policygenius, 2026). A testosterone prescription, along with the lab values and diagnosis code behind it, is exactly the kind of detail that surfaces once an APS is ordered.
Because TRT is a long-term therapy tied to cardiovascular and hematologic monitoring, underwriters want to know why you are on it, how long you have been on it, and whether your labs (hematocrit, PSA, lipids) have stayed in range. The prescription itself is rarely the issue. The underlying question is whether your overall health picture, including the condition TRT is treating, fits a standard risk profile.
Does a TRT Prescription Automatically Raise Your Rate?
No. Underwriters generally look more favorably on testosterone therapy prescribed for confirmed, lab-documented hypogonadism than on testosterone used informally for anti-aging, bodybuilding, or performance purposes without a clear diagnosis. A documented diagnosis with two low morning testosterone readings, a specific ICD-10 code, and a treating physician on record reads as a managed condition. Undocumented use, especially testosterone obtained outside a licensed clinic, reads as an unverifiable risk factor an underwriter cannot properly evaluate, which tends to push cases toward a rated table, a postponement, or a request for more records rather than an outright decline.
This is also why applicants with an active prescription should expect to disclose it accurately. Life insurance applications ask directly about current medications, and an MIB or pharmacy database check can surface a testosterone prescription that was left off the form, which underwriters treat as a nondisclosure issue rather than a medical one. That distinction, misrepresentation versus disclosed treatment, played out in a real federal case where an insurer contested a claim after records from a low-testosterone workup surfaced undisclosed sleep apnea and uncontrolled blood pressure, conditions the applicant never mentioned on his application (Winkeljohn v. Assurity Life Insurance Co., W.D. Okla., 2020). The testosterone therapy itself was not the problem; the records it generated were what exposed the earlier nondisclosure.
What About the Older Studies Linking TRT to Heart Risk?
Some of the caution baked into older underwriting guidelines traces back to two widely cited but limited studies. A 2010 trial of testosterone gel in frail, older men was stopped early after a higher rate of cardiovascular events in the treatment group (Basaria et al., New England Journal of Medicine, 2010). A 2013 retrospective analysis of VA patients similarly reported a higher risk of death, heart attack, and stroke associated with testosterone therapy (Vigen et al., JAMA, 2013). Both studies shaped a cautious posture toward TRT in medicine and, by extension, in insurance risk models for years afterward.
That picture has shifted substantially. A Stanford and Baylor cohort study that linked 509 men to the National Death Index over an average of 10 years found no significant difference in all-cause mortality between men on long-term testosterone therapy and men who were not, regardless of the type of TRT or baseline testosterone level (Eisenberg et al., International Journal of Impotence Research, 2015). Then came the TRAVERSE trial, the largest cardiovascular safety study of TRT ever conducted, which followed more than 5,000 hypogonadal men with existing heart disease or high cardiac risk and found testosterone therapy was not inferior to placebo for major adverse cardiac events (Lincoff et al., New England Journal of Medicine, 2023). That result is now the reference point clinicians and, increasingly, underwriters point to when a cardiovascular-risk objection comes up during review.
What to Expect When You Disclose TRT on an Application
Expect the underwriter to ask for, or your physician's office to be asked for, recent lab values alongside the prescription: total and free testosterone, hematocrit, PSA, and lipid panel. Elevated hematocrit is the lab flag most likely to affect your rate class on its own, since testosterone therapy can thicken blood enough to raise clotting risk if left unmonitored. A stable protocol with hematocrit under roughly 54% and normal PSA trends generally supports a standard or preferred rate.
Expect a request for an Attending Physician Statement if you are on TRT and applying for a meaningful coverage amount, since most insurers require an APS once a prescription for an ongoing hormone therapy appears on the application (Ethos, 2026). Expect the underwriter to ask about the underlying cause of your low testosterone too. Hypogonadism caused by a pituitary tumor, prior chemotherapy, or a genetic condition is evaluated differently than age-related decline, because the underlying cause carries its own separate risk profile.
